Parenteral busulfan: is therapeutic monitoring still warranted?
Grochow
Louise B
LB
Investigational Drug Branch, National Cancer Institute, Rockville, Maryland, USA.
D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods; D002066:Busulfan / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D016903:Drug Monitoring; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D007263:Infusions, Parenteral; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000628:therapy
D002066:Busulfan